AzTrials
AzTrials

Procedure-Related ComplicationPhase 2/3NCT00698880

Ipsilateral Hepatic Vein Embolization After Portal Vein Embolization

A Phase 2/3 study testing Right hepatic vein embolization in people with Procedure-Related Complication and Degree of Liver Regeneration, run by Asan Medical Center at 1 site in South Korea.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Portal vein embolization (PVE) induces shrinkage of the embolized lobe and compensatory enlargement of the non-embolized lobe, but it does not always induce sufficient liver regeneration. There was no effective method to accelerate liver regeneration in addition to PVE yet. Read more about this study

Who is it for?
Ages 20 to 75 years
What is being tested?
Right hepatic vein embolization
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
13 participants
Where
1 siteSouth Korea
Study dates
Mar 2007to Apr 2008
Phase
Phase 2/3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients showing small future remnant liver < 40% of whole liver volume

Who cannot join

  • Patients showing small future remnant liver > 40% of whole liver volume
  • Inoperable tumor extent

Trial locations and contacts

1 site in 1 country.

South Korea1 site
  • Asan Medical Center

    Seoul, Seoul, 138-736

Other trials in South Korea

About this study

Official title: Sequential Preoperative Ipsilateral Hepatic Vein Embolization After Portal Vein Embolization to Induce Further Liver Regeneration in Patients With Hepatobiliary Malignancy

Portal vein embolization (PVE) induces shrinkage of the embolized lobe and compensatory enlargement of the non-embolized lobe, but it does not always induce sufficient liver regeneration. There was no effective method to accelerate liver regeneration in addition to PVE yet.

This study intends to assess the effect of ipsilateral hepatic vein embolization (HVE) performed after Portal vein embolization (PVE) on liver regeneration. During a 1-year study period, preoperative HVE would be performed on 10 or more patients who had shown limited liver regeneration after PVE awaiting right hepatectomy. Sequential application of PVE and HVE may be safe and effective in facilitating contralateral liver regeneration by inducing more severe liver damage than PVE alone.

Read the detailed description

To prospectively assess the effect of ipsilateral HVE after PVE on liver volume change, this study was designed to continue for 12 months, from March 2007 to February 2008.

This study protocol was approved by our institutional review board, under the condition that, for patient safety, more than one occurrence of accidental coil migration into the heart or lung would lead to study discontinuation. The clinical significance of this risk had not been fully assessed, although it might not be seriously harmful. In addition, informed consent and permission for each PVE and HVE were obtained separately from each patient and/or his/her family members.

The indications for right PVE are patients undergoing right hepatectomy or more extensive liver surgery for hepatobiliary malignancy, but having small FLRs, with mean values less than 40% of total liver volume. Patients with large liver masses are excluded because their parenchymal resection rates were much lower than 60%. For patients with perihilar cholangiocarcinoma, placement of multiple biliary drains was preferred to decompress the entire biliary system, and the timing of PVE was set to when serum total bilirubin level became lower than 5 mg/dL.

The right internal jugular vein was punctured with an 18-gauge needle and a 9-F long sheath (Cook; Bloomington, IN) was inserted. The right hepatic vein (RHV) was selected using a 5-F cobra catheter (Cook) and a 0.035-inch guide wire (Terumo; Tokyo, Japan). Insertion of the guide wire toward the dorsal side was checked with a right lateral view to confirm that it was correctly inserted into the RHV. A 9-F sheath was inserted at the proximal portion of the RHV, followed by placement of a Tulip filter (retrievable vena cava filter; Cook) or a Trap-Ease filter (Cordis; Miami, FL) to prevent migration of deployed coils during embolization of the RHV. The cobra catheter was then advanced into the RHV and the main RHV branches were embolized with coils 8 to 12 mm in diameter (nester embolization coils; Cook).

Multidetector dynamic CT scans were routinely performed before PVE to assess gross liver volume change and tumor progression, and CT scans were performed every week after PVE, HVE, and hepatectomy. All CT images were reconstructed as sections 3 mm thick. The CT images were stored in a Picture Archiving and Communication System (PACS; Petavision; Asan Medical Center, Seoul, Korea), enabling image processing and various measurements including volumetry. In patients undergoing combined caudate resection, the volume of the caudate lobe was not included in the FLR volume. TLV and FLR volume before PVE were used as the baseline liver volumes for liver size comparison.

To assess the histological changes in the livers, 1 cm-sized pieces of liver tissue were excised from the ventral margins of the right posterior section, right anterior section, and left lateral section just after laparotomy. These samples were immediately fixed with 4% paraformaldehyde phosphate solution.

Immunohistochemical stainings were performed using antibody against albumin to assess the synthetic function of the hepatocytes, antibody against proliferating cell nuclear antigen (anti-PCNA) to assess cell replication, and antibody against cleaved caspase-3 to assess apoptosis. Apoptosis was also assayed by terminal deoxynucleotidyl transferase-mediated dUTP-digoxigenin nick-end labeling (TUNEL) staining. Western blots using antibodies against the acute phase proteins TNF-α, caspase-3, Bax, and Bcl-2 were performed to assess the status of proinflammatory cytokine responses. PCNA-positive and caspase-3-positive events were counted in five randomly selected high-power fields on microphotographs.

Specimens for histological examination and histomorphometric analysis were stained with hematoxylin and eosin (H-E). For hepatocyte counts, 10 different HPFs in the same slide were randomly selected.

Being tested
Right hepatic vein embolization
Keywords
Portal vein embolization, Hepatic vein embolization, Liver regeneration

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Right hepatic vein embolizationProcedure or surgery

    Also called Sequential right hepatic vein embolization

    Embolization of the right hepatic vein

Study groups in NCT00698880
Study groupRoleWhat they receive
HVEActive comparatorHepatic vein embolization after portal vein embolization
Receives: Procedure: Right hepatic vein embolization
PVENo interventionOnly portal vein embolization, historical control group

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Future remnant left liver volume on multidetector dynamic CT scans

    Measured: 2 weeks after HVE

Secondary outcomes (1)
  1. Immunohistochemical stainings

    Measured: during operation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jun 2008 (estimated)
  2. Study startMar 2007
  3. Primary completionFeb 2008
  4. Study completionApr 2008

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
13 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00698880
Sponsor's protocol ID
Preop_PVE_HVE
Status last verified
Jun 2008
First submitted
16 Jun 2008
Last updated
17 Jun 2008
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing Right hepatic vein embolization in people with Procedure-Related Complication and Degree of Liver Regeneration, run by Asan Medical Center at 1 site in South Korea.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Jun 2008. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Future remnant left liver volume on multidetector dynamic CT scans (time frame: 2 weeks after HVE). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jun 2008.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in